<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04508244</url>
  </required_header>
  <id_info>
    <org_study_id>IRGC-05-SI-18-293</org_study_id>
    <nct_id>NCT04508244</nct_id>
  </id_info>
  <brief_title>Beta Blocker Use In Traumatic Brain Injury Based On The High-Sensitive Troponin T Status</brief_title>
  <acronym>BBTBBT</acronym>
  <official_title>Beta Blocker Use In Traumatic Brain Injury Based On The High-Sensitive Troponin T Status: A Randomized Controlled Trial (BBTBBT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamad Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hamad Medical Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Beta blockers (BB) play an important role in protection of end organs that are susceptible&#xD;
      for secondary injury by the Traumatic brain injury (TBI)-induced catecholamine surge.&#xD;
      However, use of BBs in trauma patients is not yet the standard of care which necessitates&#xD;
      clear scientific evidence and justification to be used especially in TBI patients. The BBTBBT&#xD;
      study aims to determine whether early administration of propranolol based on the HSTnT status&#xD;
      will improve the outcome of mild-to-severe TBI patients. Our primary hypothesis is that BBs&#xD;
      are effective in reducing 10 and 30-day mortality in TBI patients.BBs are effective in&#xD;
      reducing 10 and 30-day mortality in TBI patients.&#xD;
&#xD;
      Methods/Design: The BBTBBT study is a prospective, randomized, double-blinded,&#xD;
      placebo-controlled trial, three-arm trial of BB use in mild-to-severe TBI patients based on&#xD;
      the HsTnT status.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Traumatic brain injury (TBI) accounts for up to 30% of all injury-related deaths [1]. It also&#xD;
      poses a significant morbidity and economic burden world-wide [2,3]. While there has been&#xD;
      significant advances in trauma care overall, there are limited medical management options for&#xD;
      head injury. Based on retrospective observational studies, TBI is associated with an&#xD;
      increased risk of mortality. Some of these studies reported higher rate of mortality in TBI&#xD;
      patients who had elevated serum troponin in comparison to those who had normal troponin, even&#xD;
      in isolated TBI.&#xD;
&#xD;
      Few studies have evaluated the clinical significance of the release of serum cardiac&#xD;
      troponins after trauma [4-7]. Some of these studies showed that elevated troponin could&#xD;
      reflect the degree of severity of overall body injury, but in particular the severity of&#xD;
      thorax trauma regardless of cardiac involvement [5,6]. Furthermore, elevated troponins were&#xD;
      reported in acute non-traumatic head injury, including acute stroke (≈27%), and subarachnoid&#xD;
      hemorrhage (≈20%) [4, 7]. However, the precise mechanism of elevated troponin is difficult to&#xD;
      be determined due to the multitude of prevailing clinical circumstances which may influence&#xD;
      troponin release. Moreover, the clinical significance and prognostic value of elevated&#xD;
      troponins levels and immune response remain poorly explored in TBI patients. Earlier studies&#xD;
      relied mainly on TnT or TnI and did not examine the newer high-sensitive TnT (HsTnT) which&#xD;
      has more sensitivity and shorter time to detect myocardial damage. A recent meta-analysis&#xD;
      showed that elevated troponins are commonly seen in critically-ill patients even in the&#xD;
      absence of coronary artery disease [7,8,9] with a prevalence of 45% studies utilized&#xD;
      conventional troponin assays ( TnT and TnI), [10] however, this figure reaches 62% with the&#xD;
      use of HsTnT [11, 12]. From the therapeutic point of view, BBs use was reported to have&#xD;
      better survival in blunt TBI patients [4, 14, 15,16]. Notably, BBs play an important role in&#xD;
      protection of end organs that are susceptible for secondary injury by the TBI-induced&#xD;
      catecholamine surge [4]. Upon the latter observation, the use of HsTnT test early in TBI&#xD;
      cases may allow early stratification and therapy to possibly reduce mortality. However, this&#xD;
      assumption needs further support through large clinical trials. Prospective studies that link&#xD;
      the release of troponins and mortality in post-TBI patients are lacking. The use of BBs in&#xD;
      patients with acute coronary myocardial injury is evidence-based, especially in the very&#xD;
      early hours post myocardial injury. However, use of BBs in trauma patients is not yet the&#xD;
      standard of care. The use of BBs needs to be clearly justified in TBI patients.&#xD;
      Retrospectively, Salim et al [13] reported that patients with severe TBI who did not receive&#xD;
      BBs had a mortality rate of 36% vs. 24% in those who were receiving BBs (p=0.036).&#xD;
      Furthermore, if troponin I was elevated on admission, the hospital mortality increased to&#xD;
      48.5% in patients without BBs therapy vs. 22.4% in those who were using BBs&#xD;
      (p=0.026).However, the two groups (with &amp; without BB) were comparable for mortality, if the&#xD;
      admission troponin values were not elevated (p=0.31). In brief, the utmost benefit in&#xD;
      survival occurred in BBs use group based on the troponin positivity on admission. However,&#xD;
      this study did not explain the specific underlying mechanism of troponin positivity. The&#xD;
      BBTBBT study is a prospective, randomized, double-blinded, placebo-controlled trial,&#xD;
      three-arm trial of BB use in mild-to-severe TBI patients based on the HsTnT status. We&#xD;
      hypothesized that early administration of BBs has beneficial effect on the 10 and 30-day&#xD;
      mortality in patients with mild-to-severe TBI based on the admission HsTnT status.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 29, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized, double-blinded, placebo-controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>10 days</time_frame>
    <description>Number of participants who died from each study arm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Number of participants who died from each study arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay</measure>
    <time_frame>3 months</time_frame>
    <description>number of days in the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional status</measure>
    <time_frame>3 months</time_frame>
    <description>Glasgow Outcome scale (range 1-8); higher scores mean a better outcome</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Injury severity indicators</measure>
    <time_frame>48 hours</time_frame>
    <description>correlation between blood biomarkers and head CT scan findings</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">771</enrollment>
  <condition>Trauma</condition>
  <condition>Brain Injuries</condition>
  <condition>Stress Reaction</condition>
  <condition>Beta Blockers</condition>
  <condition>Troponin</condition>
  <arm_group>
    <arm_group_label>TBI with positive troponin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive IV propranolol for 6 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TBI with negative troponin (a)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive IV placebol for 6 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TBI with negative troponin (b)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive IV propranolol for 6 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>12 ampoules of 1 mg placebo solution (3 ampoules/day for 2 days; 2 ampoules/day for day-3 &amp; 4 and 1 ampoule/day for day-5 &amp; 6.</description>
    <arm_group_label>TBI with negative troponin (a)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>12 ampoules of 1 mg placebo solution (3 ampoules/day for 2 days; 2 ampoules/day for day-3 &amp; 4 and 1 ampoule/day for day-5 &amp; 6.</description>
    <arm_group_label>TBI with negative troponin (b)</arm_group_label>
    <arm_group_label>TBI with positive troponin</arm_group_label>
    <other_name>inderal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All adults (≥18 -65 years)&#xD;
&#xD;
          -  both genders&#xD;
&#xD;
          -  mild-to-severe blunt TBI (head AIS 1-5 and/ GCS 4-15) patients requiring hospital&#xD;
             admission&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients &lt;18 and&gt; 65 yrs old&#xD;
&#xD;
          -  penetrating trauma&#xD;
&#xD;
          -  non-survivable injuries (head AIS=6 &amp; GCS=3)&#xD;
&#xD;
          -  uncontrolled bleeding on arrival to ED&#xD;
&#xD;
          -  pregnant women&#xD;
&#xD;
          -  prisoners&#xD;
&#xD;
          -  patients with heart rate (HR) ≤70, systolic blood pressure (SBP) ≤100 mmHg (or MAP &lt;70&#xD;
             mmHg) not responding to initial management or required to be maintained on&#xD;
             vasopressors on arrival .&#xD;
&#xD;
          -  Patients who will undergo hypothermia therapy,&#xD;
&#xD;
          -  any penetrating injury to head, thorax or abdomen,&#xD;
&#xD;
          -  history of bronchial asthma&#xD;
&#xD;
          -  patients posted for emergency surgery during the first 6 hrs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ayman El-Menyar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hamad Medical Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ayman El-Menyar, MD</last_name>
    <phone>44396130</phone>
    <email>aelmenyar@hamad.qa</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohammad Asim, PhD</last_name>
    <email>masim1@hamad.qa</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hamad General Hospital</name>
      <address>
        <city>Doha</city>
        <country>Qatar</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayman El-Menyar, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Qatar</country>
  </location_countries>
  <reference>
    <citation>Faul M, Xu L, Wald MM, Coronado VG. Traumatic Brain Injury in the United States: Emergency Department Visits, Hospitalizations, and Deaths. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Injury Prevention and Control; 2010.</citation>
  </reference>
  <reference>
    <citation>Ma VY, Chan L, Carruthers KJ. Incidence, prevalence, costs, and impact on disability of common conditions requiring rehabilitation in the United States: stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, osteoarthritis, rheumatoid arthritis, limb loss, and back pain. Arch Phys Med Rehabil. 2014 May;95(5):986-995.e1. doi: 10.1016/j.apmr.2013.10.032. Epub 2014 Jan 21. Review.</citation>
    <PMID>24462839</PMID>
  </reference>
  <reference>
    <citation>Mock C, Lormand JD, Goosen J, Joshipura M, Peden M. Guidelines for essential trauma care. Geneva, World Health Organization, 2004. Retrieved from: http://www.who.int/violence_injury_prevention/publications/services/en/guidelines_traumacare.pdf</citation>
  </reference>
  <reference>
    <citation>Al-Otaiby MA, Al-Amri HS, Al-Moghairi AM. The clinical significance of cardiac troponins in medical practice. J Saudi Heart Assoc. 2011 Jan;23(1):3-11. doi: 10.1016/j.jsha.2010.10.001. Epub 2010 Oct 20.</citation>
    <PMID>23960628</PMID>
  </reference>
  <reference>
    <citation>Mahmood I, El-Menyar A, Dabdoob W, Abdulrahman Y, Siddiqui T, Atique S, Arumugam SK, Latifi R, Al-Thani H. Troponin T in Patients with Traumatic Chest Injuries with and without Cardiac Involvement: Insights from an Observational Study. N Am J Med Sci. 2016 Jan;8(1):17-24. doi: 10.4103/1947-2714.175188.</citation>
    <PMID>27011943</PMID>
  </reference>
  <reference>
    <citation>Edouard AR, Felten ML, Hebert JL, Cosson C, Martin L, Benhamou D. Incidence and significance of cardiac troponin I release in severe trauma patients. Anesthesiology. 2004 Dec;101(6):1262-8.</citation>
    <PMID>15564931</PMID>
  </reference>
  <reference>
    <citation>Hasanin A, Kamal A, Amin S, Zakaria D, El Sayed R, Mahmoud K, Mukhtar A. Incidence and outcome of cardiac injury in patients with severe head trauma. Scand J Trauma Resusc Emerg Med. 2016 Apr 27;24:58. doi: 10.1186/s13049-016-0246-z. Erratum in: Scand J Trauma Resusc Emerg Med. 2016;24:79.</citation>
    <PMID>27121183</PMID>
  </reference>
  <reference>
    <citation>Smith A, John M, Trout R, Davis E, Moningi S. Elevated cardiac troponins in sepsis: what do they signify? W V Med J. 2009 Jul-Aug;105(4):29-32.</citation>
    <PMID>19585902</PMID>
  </reference>
  <reference>
    <citation>Lim W, Cook DJ, Griffith LE, Crowther MA, Devereaux PJ. Elevated cardiac troponin levels in critically ill patients: prevalence, incidence, and outcomes. Am J Crit Care. 2006 May;15(3):280-8; quiz 289.</citation>
    <PMID>16632770</PMID>
  </reference>
  <reference>
    <citation>Poe S, Vandivier-Pletsch RH, Clay M, Wong HR, Haynes E, Rothenberg FG. Cardiac Troponin Measurement in the Critically Ill: Potential for Guiding Clinical Management. J Investig Med. 2015 Dec;63(8):905-15. doi: 10.1097/JIM.0000000000000239.</citation>
    <PMID>26425879</PMID>
  </reference>
  <reference>
    <citation>Salim A, Hadjizacharia P, Brown C, Inaba K, Teixeira PG, Chan L, Rhee P, Demetriades D. Significance of troponin elevation after severe traumatic brain injury. J Trauma. 2008 Jan;64(1):46-52. doi: 10.1097/TA.0b013e31815eb15a.</citation>
    <PMID>18188098</PMID>
  </reference>
  <reference>
    <citation>Bukur M, Mohseni S, Ley E, Salim A, Margulies D, Talving P, Demetriades D, Inaba K. Efficacy of beta-blockade after isolated blunt head injury: does race matter? J Trauma Acute Care Surg. 2012 Apr;72(4):1013-8. doi: 10.1097/TA.0b013e318241bc5b. Erratum in: J Trauma Acute Care Surg. 2012 Jun;72(6):1725. Mosheni, Shahin [corrected to Mohseni, Shahin].</citation>
    <PMID>22491619</PMID>
  </reference>
  <reference>
    <citation>Schroeppel TJ, Fischer PE, Zarzaur BL, Magnotti LJ, Clement LP, Fabian TC, Croce MA. Beta-adrenergic blockade and traumatic brain injury: protective? J Trauma. 2010 Oct;69(4):776-82. doi: 10.1097/TA.0b013e3181e981b8.</citation>
    <PMID>20938265</PMID>
  </reference>
  <reference>
    <citation>Ko A, Harada MY, Barmparas G, Thomsen GM, Alban RF, Bloom MB, Chung R, Melo N, Margulies DR, Ley EJ. Early propranolol after traumatic brain injury is associated with lower mortality. J Trauma Acute Care Surg. 2016 Apr;80(4):637-42. doi: 10.1097/TA.0000000000000959.</citation>
    <PMID>26808028</PMID>
  </reference>
  <reference>
    <citation>El-Menyar A, Asim M, Latifi R, Bangdiwala SI, Al-Thani H. Predictive value of positive high-sensitivity troponin T in intubated traumatic brain injury patients. J Neurosurg. 2018 Dec 1;129(6):1541-1549. doi: 10.3171/2017.7.JNS17675.</citation>
    <PMID>29303440</PMID>
  </reference>
  <reference>
    <citation>El-Menyar A, Goyal A, Latifi R, Al-Thani H, Frishman W. Brain-Heart Interactions in Traumatic Brain Injury. Cardiol Rev. 2017 Nov/Dec;25(6):279-288. doi: 10.1097/CRD.0000000000000167. Review.</citation>
    <PMID>28984668</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 24, 2020</study_first_submitted>
  <study_first_submitted_qc>August 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2020</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>propranolol</keyword>
  <keyword>troponin</keyword>
  <keyword>biomarkers</keyword>
  <keyword>myocardial injury</keyword>
  <keyword>brain injury</keyword>
  <keyword>trauma</keyword>
  <keyword>qatar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Fractures, Stress</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>data sharing agreement should be signed with the MRC and legal affair at HMC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

